Model of polymicrobial peritonitis that induces the proinflammatory and immunosuppressive phases of sepsis

Infection and Immunity

Volumn 79, Issue 3, 2011, Pages 1280-1288

  Barrera, Gabriela ^a   Landoni, Verónica ^a   Martire Greco, Daiana ^a   Chiarella, Paula ^a   Meiss, Roberto ^a   Gómez, Sonia A ^b   Alves Rosa, Fernanda ^c   Rearte, Barbara ^a   Isturiz, Martín ^a   Palermo, Marina S ^a   Fernández, Gabriela C ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c Universidad Latina de Panama and Universidad Interamericana de Panama   (Panama)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL PERITONITIS; BACTERIUM CULTURE; CYTOKINE PRODUCTION; HEPATITIS; HISTOPATHOLOGY; HUMORAL IMMUNITY; INNATE IMMUNITY; INTESTINE FLORA; LEUKOCYTE ACTIVATION; LEUKOCYTOSIS; LEUKOPENIA; LIVER INJURY; LUNG INFECTION; LYMPHOCYTE PROLIFERATION; MALE; MORTALITY; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; T LYMPHOCYTE;

ANIMALS; CECUM; CYTOKINES; DISEASE MODELS, ANIMAL; INFLAMMATION; MICE; MICE, INBRED BALB C; PERITONEUM; PERITONITIS; SEPSIS;

EID: 79952290188     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01127-10     Document Type: Article

References (50)

1. Adib-Conquy, M., and J. M. Cavaillon. 2009. Compensatory anti-inflammatory response syndrome. Thromb. Haemost. 101:36-47.
2. Aldridge, A. J. 2002. Role of the neutrophil in septic shock and the adult respiratory distress syndrome. Eur. J. Surg. 168:204-214.
3. Angus, D. C., and R. S. Wax. 2001. Epidemiology of sepsis: an update. Crit. Care Med. 29:S109-S116.
4. Atochina, O., T. Daly-Engel, D. Piskorska, E. McGuire, and D. A. Harn. 2001. A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Grl(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism. J. Immunol. 167:4293-4302.
5. Bengualid, V., H. Singh, V. Singh, and J. Berger. 2008. An increase in the incidence of anaerobic bacteremia: true for tertiary care referral centers but not for community hospitals? Clin. Infect. Dis. 46:323-324.
6. Benjamim, C. F., C. M. Hogaboam, and S. L. Kunkel. 2004. The chronic consequences of severe sepsis. J. Leukoc. Biol. 75:408-412.
7. Bone, R. C. 1996. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24:1125-1128.
8. Bone, R. C., et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
9. Bosscha, K., T. J. van Vroonhoven, and C. van der Werken. 1999. Surgical management of severe secondary peritonitis. Br. J. Surg. 86:1371-1377.
10. Cervera, C., M. Almela, J. A. Martinez-Martinez, A. Moreno, and J. M. Miro. 2009. Risk factors and management of Gram-positive bacteraemia. Int. J. Antimicrob. Agents 34(Suppl. 4):S26-S30.
11. Deitch, E. A. 1998. Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11. (Pubitemid 128463868)
12. Docke, W. D., et al. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678-681.
13. Egan, C. E., W. Sukhumavasi, A. L. Bierly, and E.Y. Denkers. 2008. Understanding the multiple functions of Gr-1(+) cell subpopulations during microbial infection. Immunol. Res. 40:35-48.
14. Fan, H., and J. A. Cook. 2004. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10:71-84.
15. Farthmann, E. H., and U. Schoffel. 1998. Epidemiology and pathophysiology of intraabdominal infections (IAI). Infection 26:329-334. (Pubitemid 28466517)
16. Fenner, L., A. F. Widmer, C. Straub, and R. Frei. 2008. Is the incidence of anaerobic bacteremia decreasing? Analysis of 114,000 blood cultures over a ten-year period. J. Clin. Microbiol. 46:2432-2434.
17. Fernandez, G. C., et al. 2005. Differential expression of function-related antigens on blood monocytes in children with hemolytic uremic syndrome. J. Leukoc. Biol. 78:853-861.
18. Fink, M. P., and S. O. Heard. 1990. Laboratory models of sepsis and septic shock. J. Surg. Res. 49:186-196.
19. Goldstein, E. J. 1996. Anaerobic bacteremia. Clin. Infect. Dis. 23(Suppl. 1): S97-S101.
20. Groeneveld, A. B., A. N. Tacx, A. W. Bossink, G. J. van Mierlo, and C. E. Hack. 2003. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin. Immunol. 106:106-115.
21. Kale, I. T., M. A. Kuzu, H. Berkem, R. Berkem, and N. Acar. 1998. The presence of hemorrhagic shock increases the rate of bacterial translocation in blunt abdominal trauma. J. Trauma 44:171-174. (Pubitemid 28095839)
22. Katz, S., M. A. Jimenez, W. E. Lehmkuhler, and J. L. Grosfeld. 1991. Liver bacterial clearance following hepatic artery ligation and portacaval shunt. J. Surg. Res. 51:267-270.
23. Kusmartsev, S. A., Y. Li, and S. H. Chen. 2000. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165:779-785.
24. Landelle, C., et al. 2008. Nosocomial infection after septic shock among intensive care unit patients. Infect. Control Hosp. Epidemiol. 29:1054-1065.
25. Maier, S., et al. 2004. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 21:505-511.
26. Makarenkova, V. P., V. Bansal, B. M. Matta, L. A. Perez, and J. B. Ochoa. 2006. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176:2085-2094.
27. Mencacci, A., et al. 2002. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J. Immunol. 169:3180-3190. (Pubitemid 35013164)
28. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. (Pubitemid 14203433)
29. Murray, P. R., et al. (ed.). 2007. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
30. National Institutes of Health. 1985. Guide for the care and use of laboratory animals. Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD.
31. Neumann, B., et al. 1999. Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Int. Immunol. 11:217-227.
32. Oberhoffer, M., et al. 1999. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit. Care Med. 27:1814-1818.
33. O'Boyle, C. J., et al. 1998. Microbiology of bacterial translocation in humans. Gut 42:29-35. (Pubitemid 28228384)
34. Osuchowski, M. F., K. Welch, J. Siddiqui, and D. G. Remick. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177:1967-1974.
35. Reddy, R. C., G. H. Chen, P. K. Tekchandani, and T. J. Standiford. 2001. Sepsis-induced immunosuppression: from bad to worse. Immunol. Res. 24:273-287.
36. Remick, D. G., G. R. Bolgos, J. Siddiqui, J. Shin, and J. A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467.
37. Richardson, J. D., M. M. DeCamp, R. N. Garrison, and D. E. Fry. 1982. Pulmonary infection complicating intra-abdominal sepsis: clinical and experimental observations. Ann. Surg. 195:732-738.
38. Rittirsch, D., L. M. Hoesel, and P. A. Ward. 2007. The disconnect between animal models of sepsis and human sepsis. J. Leukoc. Biol. 81:137-143.
39. Spittler, A., et al. 2000. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin. Infect. Dis. 31:1338-1342.
40. Sterns, T., N. Pollak, B. Echtenacher, and D. N. Mannel. 2005. Divergence of protection induced by bacterial products and sepsis-induced immune suppression. Infect. Immun. 73:4905-4912.
41. Talmadge, J. E. 2007. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13:5243-5248.
42. Uchiyama, T., and D. M. Jacobs. 1978. Modulation of immune response by bacterial lipopolysaccharide (LPS): cellular basis of stimulatory and inhibitory effects of LPS on the in vitro IgM antibody response to a T-dependent antigen. J. Immunol. 121:2347-2351.
43. Uchiyama, T., and D. M. Jacobs. 1978. Modulation of immune response by bacterial lipopolysaccharide (LPS): multifocal effects of LPS-induced suppression of the primary antibody response to a T-dependent antigen. J. Immunol. 121:2340-2346.
44. Vincent, J. L., et al. 2006. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med. 34:344-353.
45. Vincent, J. L., Q. Sun, and M. J. Dubois. 2002. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34:1084-1093.
46. Vincent, J. L., F. Taccone, and X. Schmit. 2007. Classification, incidence, and outcomes of sepsis and multiple organ failure. Contrib. Nephrol. 156:64-74.
47. Wang, X., R. Andersson, J. Ding, L. Norgren, and S. Bengmark. 1993. Reticuloendothelial system function following acute liver failure induced by 90% hepatectomy in the rat. HPB Surg. 6:151-162. (Pubitemid 23127943)
48. Wichterman, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 29:189-201.
49. Wittmann, D. H., M. Sehein, and R. E. Condon. 1996. Management of secondary peritonitis. Ann. Surg. 224:10-18.
50. Xiao, H., J. Siddiqui, and D. G. Remick. 2006. Mechanisms of mortality in early and late sepsis. Infect. Immun. 74:5227-5235.